HIMS Stock Slides: AI Ambitions vs. Competition

Shares of Hims & Hers Health, Inc. slipped 1% in overnight trading. This comes as investors weigh increased competition from WeightWatchers and Eli Lilly against the company's growing AI ambitions. HIMS stock had jumped 2% on Thursday to $28.01, putting shares on track for a second straight weekly gain. CEO Andrew Dudum praised Anthropic's recent AI breakthrough, calling it a potential game-changer for healthcare. Anthropic reported that its Claude models are accelerating AI development, creating a possible path toward recursive self-improvement. Their engineers are now shipping eight times more code per quarter than they did between 2021 and 2025. What's interesting is Hims is working to expand beyond telehealth prescriptions into a full healthcare ecosystem. Last week, the company added partners like iFIT, Ladder, and Dexcom's Stelo continuous glucose monitor to its Hims & Hers Benefits platform. This expands its reach into fitness, nutrition, and women's health. AI is a key part of this vision. Last month, Hims launched Labs AI, an AI healthcare assistant that helps users understand lab results and long-term health risks. The company also recently launched generic Semaglutide in Canada. The bottom line is that Hims is betting on AI and expanded services to counter rising competition in the healthcare market.